Cyclopharm Limited (ASX: CYC) provides an update on progressing its strategy during FY19, which includes expectations for its full year results and advancement of certain operational matters, including acquiring United States Food and Drug Administration (USFDA) approval to begin commercial launch of TechnegasTM into the US in 2020.
- US commercial launch expected in 2020 and the company is building sales support for rapid market entry;
- The company has received $3.0 million AusIndustry R&D refund from the ATO;
- FY2019 sales expected to be in line with previous year.
At AEST 01:29PM, the stock was trading at $1.065 per share, no change from its previous close